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method should be used instead of OLS to avoid selection bias
due to censoring.
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OBJECTIVES: A survey was conducted to compare smoking
behavior and self-reported respiratory symptoms of persons with
and without diagnosed COPD. METHODS: In a study con-
ducted within the Saskatchewan Health database, persons over
40 years old with diagnosed COPD, emphysema or chronic
bronchitis and at least two bronchodilator prescriptions within
six months of respiratory diagnosis were identiﬁed (N = 11,493).
An age/gender matched comparison group without COPD,
asthma or any respiratory diagnoses or medications was identi-
ﬁed (N = 22,986). A survey was mailed to an age/gender strati-
ﬁed random sample of 4002 subjects, half from the COPD group
and half from the comparison group. RESULTS: The response
rate was 41% among COPD patients and 40% in the compari-
son group. Among those with COPD, 80% had ever smoked,
compared with 53% of those without COPD (OR: 4.01, CI:
3.19–5.04). Among ever smokers, 16% of COPD and 11% of
non-COPD subjects were current smokers (OR: 1.58, CI:
1.09–2.29). A large proportion of the smokers, 73% in the
COPD group and 49% in the non-COPD group, had smoked
for over 30 years. Odds ratios for self-reported symptoms of
COPD comparing the COPD cohort to non-COPD were 11.0
(CI: 8.1–15.1) for persistent cough, 10.4 (CI: 8.1–13.6) for
phlegm with cough, 25.1 (CI: 18.5–34.0) for wheezing, and 18.5
(CI: 13.8–24.8) for shortness of breath with mild exercise.
Among the subjects classiﬁed as non-COPD, 20% reported
having any of the above-mentioned respiratory symptoms and
only 2% reported having all four symptoms. CONCLUSIONS:
Persons with diagnosed COPD are more likely to have been
smokers in the past and had a longer smoking history than
persons without COPD. Crude measures such as the proportion
that ever smoked may not capture substantial differences in
smoking-related illness. Self-reported respiratory symptoms sup-
ported the categorization of COPD vs. non-COPD made using
administrative data.
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OBJECTIVES: To determine the inﬂuence of anemia on hospi-
talization and mortality in elderly patients with chronic obstruc-
tive pulmonary disease (COPD) and chronic kidney disease
(CKD). METHODS: We identiﬁed ambulatory patients over age
65 who had at least one outpatient hemoglobin lab between
1998 to 2002. Patients were identiﬁed using a medical record
data repository from a large health care system in Western Penn-
sylvania. COPD was identiﬁed using ICD-9 coding and CKD was
deﬁned as having at least 2 GFR measurements <60ml/min sep-
arated by at least 3 weeks. Demographic, comorbidity, labora-
tory, and visit data were collected. Anemia was deﬁned by WHO
criteria as a hemoglobin <13g/dL in males and <12g/dL in
females. Cox proportional hazard models were used to estimate
the hazard ratio of ﬁrst hospitalization and death by adjusting
for demographics and comorbidities. Hazard ratios of anemic
and non-anemic cohorts were compared. RESULTS: There were
895 elderly patients (47% male; 87% white) identiﬁed with
COPD and CKD. Comorbidities included hypertension in 86%,
heart failure in 78%, and diabetes in 54% of patients. Males had
higher rates of anemia (58% versus 49%, p = 0.006). Compared
to non-anemic patients, those with anemia had a higher rate of
hospitalization within 1 year (hazard ratio = 1.34, 95% CI: 1.14,
1.57). Mean inpatient days during the study timeframe were
higher for anemic patients (51 verses 44 days, p = 0.03). The
adjusted hazard ratio for all-cause mortality in anemic patients
was 1.52 (95% CI: 1.18, 1.99). Mean survival time for anemic
patients was 44.5 months and for non-anemic patients was 48.9
months (p = 0.003). CONCLUSIONS: The results of this study
suggest that anemia is associated with a signiﬁcant increase in
the risk of hospitalization and death in elderly patients with
COPD and CKD after adjusting for other comorbidities. The
effect of anemia management on these outcomes should be eval-
uated in prospective clinical trials.
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OBJECTIVES: In preparation for exploring the potential cost-
effectiveness of inhaled corticosteroids (ICS) for the treatment of
chronic obstructive pulmonary disease (COPD), we explored the
costs and outcomes of patients with COPD in the presence of
missing data. METHODS: Using data on 751 patients enrolled
in the ISOLDE randomized controlled trial that received either
ﬂuticasone propionate or placebo, the outcomes studied were
COPD exacerbations, successfully treated weeks, rate of decline
in FEV1, costs, survival and health status. In line with the orig-
inal clinical analysis, costs and outcomes were estimated using a
hierarchical multilevel model assuming data were missing at
random. Further analyses explored the use of quality-adjusted
survival techniques for health outcomes as well as multiple impu-
tation methods to address missing data issues. RESULTS: In the
base case analysis we estimated the incremental costs of ICS
versus placebo to be £900 (95% conﬁdence interval (CI): 100;
1700) and the additional effect of 0.59 (CI: 0; 1.3) exacerbations
avoided and 3 (CI: 1.7; 4.5) successfully treated weeks. We
explored the robustness of these results to alternative assump-
tions in extensive sensitivity analysis. While survival was higher
